1 – Weber, G., Adamczyk, A., Freytag, S., “Treatment of Acne with a Yeast Preparation,” Fortschritte der Medizin 107.26 (1989): 563-566, https://europepmc.org/abstract/MED/2530145.
2 – Höchter W., Chase D., Hagenhoff, G., “Saccharomyces boulardii in Acute Adult Diarrhea: Efficacy and Tolerance of Treatment,” Munchener Medizinische Wochenschrift, 132 (1990): 188–192.
3 – McFarland, L.V. “Meta-analysis of Probiotics for the Prevention of Traveler’s Diarrhea,” Travel Medicine and Infectious Disease, 5.2 (2007):97-105.
4 – Czerucka, D., Dahan, S., Mograbi, B., Rossi, B., Rampal, P., “Saccharomyces boulardii Preserves the Barrier Function and Modulates the Signal Transduction Pathway induced in Enteropathogenic Escherichia coli-Infected T84 Cells,” Infection and Immunity, 68.10 (2000): 5998-6004.
5 – Maupas, J., Champemont, P., Delforge, M., “Treatment of Irritable Bowel Syndrome with Saccharomyces boulardii: a Double Blind, Placebo Controlled Study,” Médecine & Chirurgie Digestives, 12.1 (1983): 77-79.
6 – Guslandi, M., Mezzi, G., Sorghi, M., Testoni, P.A., “Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease,” Digestive Diseases and Sciences, 45.7 (2000):1462-1464.
7 – Guslandi, M., Giollo, P., Testoni, P.A., “A Pilot Trial of Saccharomyces boulardii in Ulcerative Colitis,” European Journal of Gastroenterology & Hepatology, 15.6 (2003): 679-698.
8 – Johnston, B.C., Goldenberg, J.Z., Vandvik, P.O., Sun, X., Guyatt, G.H., “Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea,” Cochrane Database of Systematic Reviews, 11 (2011): CD004827.
9 – Kotowska, M., Albrecht, P., Szajewska, H., “Saccharomyces boulardii in the Prevention of Antibiotic-Associated Diarrhea in Children: a Randomized Double-Blind Placebo-Controlled Trial,” Alimentary Pharmacology & Therapeutics, 21.5 (2005): 583-590.
10 – McFarland, L., Surawicz, C., Greenberg, R., “A Randomized Placebo-Controlled Trial of Saccharomyces boulardii in Combination with Standard Antibiotics for Clostridium difficile Disease,” Journal of the American Medical Association, 271.24 (1994): 1913-1918.
11 – Szajewska, H., Horvath, A., Kołodziej, M., “Systematic Review with Meta-analysis: Saccharomyces boulardii Supplementation and Eradication of Helicobacter pylori Infection,” Alimentary Pharmacology & Therapeutics, 41.12 (2015): 1237-1245.
12 – Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P., De Meyer, R., “Response of Human and Rat Small Intestinal Mucosa to Oral Administration of Saccharomyces boulardii,” Pediatric Research, 20.2 (1986): 192-196.
13 – Dahan, S., Dalmasso, G., Imbert, V., Peyron, J.F., Rampal, P., Czerucka, D., “Saccharomyces boulardii Interferes with Enterohemorrhagic Escherichia coli-induced Signaling Pathways in T84 Cells,” Infection and Immunity, 71.2 (2003): 766-773.
14 – Buts, J.P., De Keyser, N., De Raedemaeker, L., “Saccharomyces boulardii Enhances Rat Intestinal Enzyme Expression by Endoluminal Release of Polyamines,” Pediatric Research, 36.4 (1994): 522-527.
15 – Thomas, S., Przesdzing, I., Metzke, D., Schmitz, J., Radbruch, A., Baumgart, D.C., “Saccharomyces boulardii inhibits Lipopolysaccharide-Induced Activation of Human Dendritic Cells and T Cell Proliferation,” Clinical and Experimental Immunology, 155.1 (2009): 78-87.
16 – Canani, R.B., Cucchiara, S., Cuomo, R., Pace, F., Papele, F., “Saccharomyces boulardii: a Summary of the Evidence for Gastroenterology Clinical Practice in Adults,” European Review for Medical and Pharmacological Sciences, 15 (2011): 809-822, https://www.europeanreview.org/wp/wp-content/uploads/1000.pdf.